Related Experiment Videos
Pulmonary infections in children with cystic fibrosis
1Miller Children's Hospital, Long Beach, CA 90801-1428.
Insights
Cystic Fibrosis (CF) patients face severe lung infections due to abnormal mucus and poor clearance. Treatment requires a multifaceted approach combining antibiotics with other therapies to manage these chronic respiratory issues.
Area of Science:
- Pulmonology
- Infectious Diseases
- Genetics
Background:
- Cystic Fibrosis (CF) is characterized by abnormal secretions and impaired mucociliary clearance, leading to chronic bronchopulmonary infections.
- Bacterial colonization, including Staphylococcus aureus, Hemophilus influenzae, and Pseudomonas aeruginosa, initiates a cycle of inflammation and airway obstruction.
- Early signs of CF include persistent cough, failure to thrive, and radiographic changes like hyperinflation and bronchial thickening.
Purpose of the Study:
- To review the etiology and management of pulmonary infections in Cystic Fibrosis patients.
- To discuss the evolution of antibiotic therapies and the importance of nonantimicrobial treatments.
- To highlight newer therapeutic strategies for managing respiratory infections in CF.
Main Methods:
- Review of current literature on Cystic Fibrosis pulmonary infections.
- Analysis of common pathogens and diagnostic methods (e.g., sputum culture).
- Discussion of various treatment modalities, including antibiotic strategies and novel therapies.
Main Results:
- Pulmonary infections are a primary cause of morbidity and mortality in CF patients.
- Effective treatment necessitates a combination of antimicrobial and nonantimicrobial interventions.
- Advances in potent antibiotics have improved outcomes, but a comprehensive strategy is crucial.
Conclusions:
- Managing CF lung disease requires a dynamic approach to antibiotic therapy (prevention, suppression, definitive treatment).
- Emerging therapies like aerosolized antibiotics, corticosteroids, and continuous prophylaxis offer additional benefits.
- Laboratory awareness of typical CF pathogens and appropriate testing is vital for guiding treatment.
Abstract:
Bronchopulmonary infections continue to be the major determinant of morbidity and mortality in patients with cystic fibrosis (CF). The basic pathogenesis of disease includes abnormal secretions and impaired mucociliary clearance. Colonization of the tracheobronchial tract with bacteria is then associated with a cycle of infection, inflammation and airway obstruction eventually leading to respiratory insufficiency. Early clinical features include persistent cough and failure to thrive. Hyperinflation and bronchial thickening are early radiographic changes suggestive of CF. Staphylococcus aureus is commonly the initial respiratory pathogen. Subsequently, Hemophilus influenzae and Pseudomonas aeruginosa colonize the respiratory tract. In addition, respiratory viruses and other pathogens such as Legionella and mycoplasma are implicated in the etiology of pulmonary infections. The culture of respiratory secretions such as sputum are important guidelines to the etiology of pulmonary infection in CF. The laboratory must be aware of the pathogens that are typical of this disease and use appropriate techniques and media. In large part, advances in treatment in CF over the past two decades are due to the availability of increasingly potent antibiotic agents. However, effective treatment must be multifaceted and include a variety of nonantimicrobial therapies. Different approaches to the antibiotic therapy of pulmonary infection in CF, including prevention, suppression, and definitive treatment are discussed. In addition to traditional antibiotic therapy, a variety of newer methods of therapy in CF are discussed. These include oral antipseudomonal antibiotics, corticosteroid therapy, aerosolized antibiotics, and continuous antimicrobial prophylaxis.